180 related articles for article (PubMed ID: 23092832)
21. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Sasse AD; Clark LG; Sasse EC; Clark OA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):784-91. PubMed ID: 16198504
[TBL] [Abstract][Full Text] [Related]
22. The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Wadler S; Goldberg G; Fields A; Anderson P; Beitler JJ; Sood B; Haynes H; Runowicz C
Semin Oncol; 1996 Aug; 23(4 Suppl 8):64-8. PubMed ID: 8783670
[TBL] [Abstract][Full Text] [Related]
23. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
24. Amifostine in reducing cisplatin toxicity.
Markman M
Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
[TBL] [Abstract][Full Text] [Related]
25. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
26. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
Thongprasert S; Chewaskulyong B
J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
[TBL] [Abstract][Full Text] [Related]
27. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
28. Minocycline attenuates ototoxicity and enhances antitumor activity of cisplatin treatment in vitro.
Du B; Zhang Y; Tang Y; Wang P
Otolaryngol Head Neck Surg; 2011 May; 144(5):719-25. PubMed ID: 21493367
[TBL] [Abstract][Full Text] [Related]
29. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer.
Schiller JH
Semin Oncol; 1996 Aug; 23(4 Suppl 8):78-82. PubMed ID: 8783672
[TBL] [Abstract][Full Text] [Related]
30. Understanding platinum-induced ototoxicity.
Langer T; am Zehnhoff-Dinnesen A; Radtke S; Meitert J; Zolk O
Trends Pharmacol Sci; 2013 Aug; 34(8):458-69. PubMed ID: 23769626
[TBL] [Abstract][Full Text] [Related]
31. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
32. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
33. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Church MW; Blakley BW; Burgio DL; Gupta AK
J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
[TBL] [Abstract][Full Text] [Related]
34. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
35. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
36. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
Schiller JH; Storer B; Berlin J; Wittenkeller J; Larson M; Pharo L; Larson M; Berry W
J Clin Oncol; 1996 Jun; 14(6):1913-21. PubMed ID: 8656260
[TBL] [Abstract][Full Text] [Related]
37. A Revision in Evaluating the Results of Intratympanic Otoprotective Injections against Cisplatin-Induced Ototoxicity.
Safdarian M
Otolaryngol Head Neck Surg; 2016 Apr; 154(4):774-5. PubMed ID: 27045113
[No Abstract] [Full Text] [Related]
38. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer.
Freyer DR; Brock P; Knight K; Reaman G; Cabral S; Robinson PD; Sung L
Lancet Child Adolesc Health; 2019 Aug; 3(8):578-584. PubMed ID: 31160205
[TBL] [Abstract][Full Text] [Related]
39. Response to "A Revision in Evaluating the Results of Intratympanic Otoprotective Injections against Cisplatin-Induced Ototoxicity".
Naples J; Parham K
Otolaryngol Head Neck Surg; 2016 Apr; 154(4):775-6. PubMed ID: 27045114
[No Abstract] [Full Text] [Related]
40. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Van den Brande J; Nannan Panday VR; Hoekman K; Rosing H; Huijskes RV; Verheijen RH; Beijnen JH; Vermorken JB
Am J Clin Oncol; 2001 Aug; 24(4):401-3. PubMed ID: 11474273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
